Juan Andres - Jul 23, 2021 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Chief Technical Operations and Quality Officer
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Stock symbol
MRNA
Transactions as of
Jul 23, 2021
Transactions value $
-$3,292,350
Form type
4
Date filed
7/27/2021, 05:29 PM
Previous filing
Jul 23, 2021
Next filing
Jul 30, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise $61.1K +5K $12.21* 5K Jul 23, 2021 Direct F1
transaction MRNA Common Stock Sale -$1.65M -5K -100% $330.90 0 Jul 23, 2021 Direct F1
transaction MRNA Common Stock Options Exercise $61.1K +5K $12.21* 5K Jul 26, 2021 Direct F1
transaction MRNA Common Stock Sale -$1.76M -5K -100% $351.99 0 Jul 26, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -5K -1.19% $0.00 415K Jul 23, 2021 Common Stock 5K $12.21 Direct F1, F2
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -5K -1.21% $0.00 410K Jul 26, 2021 Common Stock 5K $12.21 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021.
F2 25% of this option vested and became exercisable on August 1, 2018 with the remainder vesting in 12 equal quarterly installments thereafter.

Remarks:

Chief Technical Operations and Quality Officer